KRYSTAL BIOTECH INC. - COMMON STOCK

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

18 авг 2022 17:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

08 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

01 авг 2022 18:39:37 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

06 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

07 июн 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

19 май 2022 19:30:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

09 май 2022 16:15:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

03 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

11 апр 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

28 мар 2022 11:00:00 Источник Nasdaq GlobeNewswire

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

26 мар 2022 12:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

24 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

18 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Settlement with PeriphaGen, Inc.

15 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

24 фев 2022 07:00:03 Источник Nasdaq GlobeNewswire

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

18 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

30 ноя 2021 20:15:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

29 ноя 2021 16:20:00 Источник Nasdaq GlobeNewswire